Here are the 10-K annual reports from Cerus Corp (CERS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CERS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERS filings page.
Cerus Corporation files its annual report describing its INTERCEPT blood safety business and development pipeline. The company sells pathogen-reduction systems for platelets, plasma and cryoprecipitation in the U.S. and multiple international markets, using proprietary compounds and UVA illumination to inactivate viruses, bacteria, parasites and leukocytes.
Cerus is investing heavily in an INTERCEPT red blood cell system, supported by BARDA and DoD contracts, with Phase 3 U.S. trials and a resubmitted MDR application in Europe after an earlier conformity assessment was closed. The filing highlights dependence on key suppliers and government funding, concentrated blood-center customers, extensive global regulation and the risk that the red cell program may never achieve approval or broad adoption, which could prolong operating losses.